Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Ryoko Sakai"'
Autor:
Masayoshi Harigai, Eiichi Tanaka, Eisuke Inoue, Ryoko Sakai, Naohiro Sugitani, Shigeyuki Toyoizumi, Naonobu Sugiyama, Hisashi Yamanaka
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1181-1195 (2024)
Abstract Introduction Patients with rheumatoid arthritis (RA) may have an increased malignancy risk versus the general population, potentially elevated by biological disease-modifying antirheumatic drug (bDMARD) use. Using patient registry data, we d
Externí odkaz:
https://doaj.org/article/796c6615710d4520b9bb31a6ac79d58e
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objectives To compare the risk of cardiovascular events among Janus kinase inhibitors (JAKIs), biological disease-modifying antirheumatic drugs (bDMARDs) (tumour necrosis factor inhibitors (TNFIs) and non-TNFIs) and methotrexate (MTX) in Japanese pat
Externí odkaz:
https://doaj.org/article/dfc5dfa836d24c8a8c8ce9fdff8aaaeb
Autor:
Tomokazu Shoji, Ryusei Muto, Ryoko Sakai, Hiroki Matsumura, Takashi Uchida, Fumihiko Kitta, Osamu Inoue, Keishi Kawata, Manabu Akazawa
Publikováno v:
AIMS Microbiology, Vol 8, Iss 4, Pp 528-543 (2022)
This retrospective, observational cohort study investigated the economic impact of genotype by classifying methicillin-resistant Staphylococcus aureus (MRSA) by using the polymerase chain reaction-based open reading frame typing (POT) method. Using a
Externí odkaz:
https://doaj.org/article/147c36ec8e0745188fa20a1b2aef9eb7
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-10 (2022)
Abstract Background Infection is one of the primary concerns during treatment for rheumatoid arthritis (RA) in elderly patients. However, infection risk of patients with RA receiving targeted therapy (TT) including biological disease-modifying antirh
Externí odkaz:
https://doaj.org/article/e0ae7fc72008423e8e01ab1b8c331bd9
Autor:
Waka Yokoyama-Kokuryo, Hayato Yamazaki, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Tsuneo Kondo, Seiji Nakamura, Ryoko Sakai, Fumio Hirano, Toshihiro Nanki, Ryuji Koike, Masayoshi Harigai
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-8 (2020)
Abstract Background Abatacept (ABA) is a biological disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis (RA). The aim of this study was to identify molecules that are associated with therapeutic responses to ABA in patients with RA
Externí odkaz:
https://doaj.org/article/9a125c5b757142cdaea09bf9238f9372
Publikováno v:
RMD Open; Apr2024, Vol. 10 Issue 2, p1-9, 9p
Autor:
Masayoshi Harigai, Takao Fujii, Ryoko Sakai, Ataru Igarashi, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Amika Yoshida, Norihiro Okada, Katsuhisa Yamashita, Yutaka Kawahito
Publikováno v:
Modern Rheumatology; Mar2024, Vol. 34 Issue 2, p287-296, 10p
Autor:
Masayoshi Harigai, Takao Fujii, Ryoko Sakai, Ataru Igarashi, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Amika Yoshida, Norihiro Okada, Katsuhisa Yamashita, Yutaka Kawahito
Publikováno v:
Modern Rheumatology.
Objective We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged ≥75 years with rheumatoid arthritis (RA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68abe237545cda05dcd99d76bed546f2
https://doi.org/10.1093/mr/road031
https://doi.org/10.1093/mr/road031
Autor:
Naoko Konda, Ryoko Sakai, Keigo Saeki, Yuri Matsubara, Yosikazu Nakamura, Takako Miyamae, Yoshikazu Nakaoka, Masayoshi Harigai
Publikováno v:
Modern Rheumatology.
ObjectiveWe conducted a nationwide epidemiological study to estimate the number of patients with Takayasu arteritis (TAK) and giant cell arteritis (GCA) in Japan and to describe the clinical characteristics of these patients.MethodsThe first survey w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0445533dc40e32db0c1f069de782cd64
https://doi.org/10.1093/mr/road019
https://doi.org/10.1093/mr/road019
Autor:
Katsunori Ikari, Eisuke Inoue, Naohiro Sugitani, N. Sugimoto, Kumiko Saka, R. Yamaguchi, Ryoko Sakai, Eiichi Tanaka, Mai Abe, Masayoshi Harigai, H. Yamanaka, Eri Sugano, Moeko Ochiai, Yoko Higuchi, Ayako Nakajima
Publikováno v:
Modern Rheumatology. 32:675-685
Objectives To evaluate the differences in patients’ population and efficacy/effectiveness of biological disease–modifying antirheumatic drugs (bDMARDs) between randomized controlled trials (RCTs) and clinical practice in patients with rheumatoid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c98c08911c744e128ccbbb7e4282b73d
https://doi.org/10.1093/mr/roab067
https://doi.org/10.1093/mr/roab067